Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Duramed Research Clear all

Conditions: Healthy
Interventions: Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)], Seasonique (LNG/EE and EE), Portia (LNG/EE); Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Menopause
Interventions: DR-2041a, DR-2041b, Placebo; Drug · Other
Lead sponsor: Duramed Research; Industry
Eligibility: 30 Years to 80 Years · Female only
Enrollment: 622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 97
States / cities: Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 77 more

Conditions: Endometriosis
Interventions: DR-2001a, DR-2001b, Placebo; Drug · Other
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 41
States / cities: Enterprise, Alabama • Montgomery, Alabama • Phoenix, Arizona + 38 more

Conditions: Menopause
Interventions: Synthetic Conjugated estrogens, B, Placebo; Drug · Other
Lead sponsor: Duramed Research; Industry
Eligibility: 30 Years to 80 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 38
States / cities: Huntsville, Alabama • Tucson, Arizona • Carmichael, California + 31 more

Conditions: Hot Flashes
Interventions: Cenestin 0.3 mg Tablets, Placebo; Drug · Other
Lead sponsor: Duramed Research; Industry
Eligibility: 30 Years to 80 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 49
States / cities: Huntsville, Alabama • Montgomery, Alabama • Phoenix, Arizona + 40 more

Conditions: Contraception
Interventions: DR-1011; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 2,235 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 55
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more

Conditions: Contraception
Interventions: Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 11
States / cities: Tucson, Arizona • Washington D.C., District of Columbia • Lincoln, Nebraska + 8 more

Conditions: Migraine
Interventions: 91-day Levonorgestrel Oral Contraceptive, Placebo; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 22
States / cities: La Mesa, California • San Diego, California • San Francisco, California + 18 more

Conditions: Prostate Cancer
Interventions: Cyproterone acetate 5, Placebo, Cyproterone acetate 15, Cyproterone acetate 25; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 98
States / cities: Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 87 more

Conditions: Emergency Contraception
Interventions: DR-104; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 11 Years to 16 Years · Female only
Enrollment: 343 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: San Francisco, California • Atlanta, Georgia • Minneapolis, Minnesota + 2 more

Conditions: Bone Mineral Density
Interventions: 91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 1,361 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 46
States / cities: Phoenix, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 39 more

Conditions: Nocturnal Vasomotor Symptoms
Interventions: SCE-B, Placebo; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 17
States / cities: Anaheim, California • Sacramento, California • San Diego, California + 14 more

Conditions: Amenorrhea
Interventions: DR-2021a, DR-2021b, DR-2021c, DR-2021d, DR-2021e, Placebo; Drug · Other
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 27
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 22 more

Conditions: Infertility
Interventions: DR-2011, Crinone 8%; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 1,297 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 29
States / cities: Tarzana, California • West Los Angeles, California • Westlake, California + 26 more

Conditions: Urinary Incontinence
Interventions: DR-3001a, DR-3001b, Placebo; Drug · Other
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 46
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 42 more

Conditions: Dysmenorrhea
Interventions: levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets, Placebo tablet; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: Up to 17 Years · Female only
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 13
States / cities: Denver, Colorado • Decatur, Georgia • Louisville, Kentucky + 10 more

Conditions: Contraception
Interventions: DR-1021; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,347 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 85
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 76 more

Conditions: Overactive Bladder
Interventions: Oxybutinyn Vaginal Ring 4mg, Oxybutinyn Vaginal Ring 6mg; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 35
States / cities: Phoenix, Arizona • San Diego, California • Miami, Florida + 28 more

Conditions: Breakthrough Bleeding
Interventions: DR-1031, Seasonale®, Portia®; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 567 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 50
States / cities: Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 45 more

Conditions: Infertility
Interventions: DR-2011, Progesterone 8% Vaginal Gel; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Dysmenorrhea
Interventions: levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets, levonorgestrel/EE 0.15/0.03 mg tablets and placebo; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 18
States / cities: Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 14 more

Conditions: Respiratory Tract Diseases
Interventions: DR-5001, Placebo; Biological · Other
Lead sponsor: Duramed Research; Industry
Eligibility: 17 Years and older
Enrollment: 4,040 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Great Lakes, Illinois • Fort Jackson, South Carolina

Conditions: Overactive Bladder
Interventions: DR-3001, Placebo; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 81
States / cities: Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more

Search by objective public record fields.

A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens

A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy

Evaluation of DR-2001 for the Management of Endometriosis-Related Pelvic Pain

A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy

A Clinical Trial to Demonstrate the Efficacy and Safety of Cenestin 0.3 mg for the Treatment of Hot Flashes

Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive

A Multicenter Study to Evaluate the Safety of Seasonique, an Oral Contraceptive.

A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches

A Clinical Trial to Study DR-2031 for the Treatment of Hot Flashes in Prostate Cancer Patients

Emergency Contraception Actual Use Study

A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females

Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women

A Trial to Evaluate DR-2021 in Women With Secondary Amenorrhea

A Clinical Trial to Evaluate the Efficacy and Safety of DR-2011 for In Vitro Fertilization

Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

Open-Label Study to Evaluate the Safety and Efficacy of a Low-Dose 28-Day Oral Contraceptive

A Safety Extension Study of DR-OXY-301

A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale

Comparison of DR-2011 to a Progesterone Vaginal Gel for Luteal Phase Replacement

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001

A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder